Page 77 - Read Online
P. 77

Page 12 of 16                              Chávez-López et al. Hepatoma Res 2020;6:14  I  http://dx.doi.org/10.20517/2394-5079.2019.023

               Conflicts of interest
               All authors declared that there are not conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2020.


               REFERENCES
               1.   American Cancer Society. Cancer Facts & Figures, 2019. Available from: https://www.cancer.org/content/dam/cancer-org/research/
                   cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf [Last accessed on 26 Mar 2020]
               2.   World Health Organization, Cancers, 2010. Available from: https://www.who.int/nmh/publications/fact_sheet_cancers_en.pdf [Last
                   accessed on 26 Mar 2020]
               3.   Chávez-López MG, Zúñiga-García V, Pérez-Carreón JI, Avalos-Fuentes A, Escobar Y, et al. Eag1 channels as potential early-stage
                   biomarkers of hepatocellular carcinoma. Biologics 2016;10:139-48.
               4.   Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47:S2-6.
               5.   Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
               6.   Chuang SC, La Vecchia C, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer
                   Lett 2009;286:9-14.
               7.   Gomes MA, Priolli DG, Tralhão JG, Botelho MF. Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. Rev Assoc
                   Med Bras (1992) 2013;59:514-24.
                                                                                 2+
               8.   Ali ES, Rychkov GY, Barritt GJ. Metabolic disorders and cancer: hepatocyte store-operated Ca  channels in nonalcoholic fatty liver
                   disease. Adv Exp Med Biol 2017;993:595-621.
               9.   Herbst DA, Reddy KR. Risk factors for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2012;1:180-2.
               10.  Sherman M, Llovet JM. Smoking, hepatitis B virus infection, and development of hepatocellular carcinoma. J Natl Cancer Inst
                   2011;103:1642-3.
               11.  Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol 2003;39:S59-63.
               12.  Barker BS, Young GT, Soubrance CH, Stephens GJ, Stevens EB, et al. Conn’s Translational Neuroscience, Chapter 2- Ion Channels.
                   Academic Press; 2017. pp. 11-43.
               13.  Martial S. Involvement of ion channels and transporters in carcinoma angiogenesis and metastasis. Am J Physiol Cell Physiol
                   2016;310:C710-27.
               14.  Lang F, Stournaras C. Ion channels in cancer: future perspectives and clinical potential. Philos Trans R Soc Lond B Biol Sci
                   2014;369:20130108.
               15.  Catterall WA. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol 2011;3:a003947.
               16.  Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol
                   2003;4:517-29.
                                                                       2+
               17.  Prevarskaya N, Ouadid-Ahidouch H, Skryma R, Shuba Y. Remodelling of Ca  transport in cancer: how it contributes to cancer
                   hallmarks? Philos Trans R Soc Lond B Biol Sci 2014;369:20130097.
               18.  Taylor JT, Zeng XB, Pottle JE, Lee K, Wang AR, et al. Calcium signaling and T-type calcium channels in cancer cell cycling. World J
                   Gastroenterol 2008;14:4984-91.
                                    2+
                                                                    2+
               19.  Roderick HL, Cook SJ. Ca  signalling checkpoints in cancer: remodelling Ca  for cancer cell proliferation and survival. Nat Rev Cancer
                   2008;8:361-75.
               20.  Kuang Q, Purhonen P, Hebert H. Structure of potassium channels. Cell Mol Life Sci 2015;72:3677-93.
               21.  Ramirez A, Vazquez-Sanchez AY, Carrion-Robalino N, Camacho J. Ion channels and oxidative stress as a potential link for the diagnosis
                   or treatment of liver diseases. Oxid Med Cell Longev 2016;2016:3928714.
                                           +
               22.  Pardo LA, Stuhmer W. The roles of K  channels in cancer. Nat Rev Cancer 2014;14:39-48.
               23.  Angus M, Ruben P. Voltage gated sodium channels in cancer and their potential mechanisms of action. Channels (Austin) 2019;13:400-9.
               24.  Djamgoz MBA, Onkal R. Persistent current blockers of voltage-gated sodium channels: a clinical opportunity for controlling metastatic
                   disease. Recent Pat Anticancer Drug Discov 2013;8:66-84.
               25.  Fraser SP, Ozerlat-Gunduz I, Brackenbury WJ, Fitzgerald EM, Campbell TM, et al. Regulation of voltage-gated sodium channel
                   expression in cancer: hormones, growth factors and auto-regulation. Philos Trans R Soc Lond B Biol Sci 2014;369:20130105.
               26.  Brackenbury WJ. Voltage-gated sodium channels and metastatic disease. Channels (Austin) 2012;6:352-61.
               27.  Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 2009;8:153-71.
   72   73   74   75   76   77   78   79   80   81   82